SHANGHAI, May 21 (Reuters) – Johnson & Johnson’s nipocalimab has won approval in China, the U.S. drugmaker said on its WeChat social media account Thursday.
(Reporting by Andrew Silver in ShanghaiEditing by Tomasz Janowski)
Brought to you by www.srnnews.com